Drug intelligence / Profile preview

BR3006A

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR3006A appears to be a component of BR3006, which is a drug being developed by Boryung Corp. for the treatment of Type 2 Diabetes Mellitus. BR3006A is one of three components (along with BR3006B and BR3006C) that are being studied both individually and in combination. Clinical trials have evaluated the pharmacokinetics and safety of BR3006A when co-administered with the other components compared to the single administration of BR3006.

Beyond the preview

Go deeper on BR3006A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR3006A.

Explore the full profile